Home | Welcome to Contract Pharma   
Last Updated Tuesday, July 29 2014
Print

Topics - Drug Development


Refine by Date:
From: To:
Published July 25, 2014
Aims to improve collaboration between clinical sites and pharma companies Read More »
Published July 25, 2014
To perform in-vitro cell line screening of OPDC candidates Read More »
Published July 23, 2014
Expands rare disease pipeline Read More »
Published July 17, 2014
Merged company will have operations in London, Wilmington, and Cary, NC Read More »
Published July 17, 2014
Expands injectable delivery capabilities Read More »
Published July 16, 2014
Advances ISIS-TTRRx Read More »
Published July 16, 2014
Will research T cell-based cancer therapies Read More »
Published July 15, 2014
Triggers $3 million milestone payment Read More »
Published July 15, 2014
Aims to develop and commercialize drugs targeting international and Chinese markets Read More »
Published July 9, 2014
Gains Phase II sickle cell disease drug Read More »
Published July 2, 2014
Advances HBV development program Read More »
Published July 2, 2014
Will apply GlymaxX ADCC to manufacture antibodies in preclinical and clinical development Read More »
Published July 2, 2014
Gains portfolio of next-gen SERDs to treat breast cancer Read More »
Published June 27, 2014
Expands support services for biologics development Read More »
Published June 25, 2014
Preclinical candidate has potential to treat cancer and autoimmune disorders Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On